[{"id":"7dd3a590-b696-4df9-b9c1-bbc93b505b71","acronym":"","url":"https://clinicaltrials.gov/study/NCT05890742","created_at":"2023-06-06T14:07:01.756Z","updated_at":"2024-07-02T16:35:14.772Z","phase":"Phase 3","brief_title":"A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer","source_id_and_acronym":"NCT05890742","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Tabosun (ipilimumab N01 injection)"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 05/25/2023","start_date":" 05/25/2023","primary_txt":" Primary completion: 04/15/2028","primary_completion_date":" 04/15/2028","study_txt":" Completion: 07/15/2028","study_completion_date":" 07/15/2028","last_update_posted":"2024-03-15"},{"id":"6b8da668-3452-4f5c-9ff3-8baba01ae0a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04634058","created_at":"2021-01-19T20:37:05.920Z","updated_at":"2024-07-02T16:35:56.030Z","phase":"Phase 2","brief_title":"PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment","source_id_and_acronym":"NCT04634058","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" CTLA4","pipe":"","alterations":" ","tags":["CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiLi (adebrelimab) • Tabosun (ipilimumab N01 injection)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/01/2020","start_date":" 11/01/2020","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-02-08"},{"id":"97373cd1-5c53-4fd6-80ed-8a4493c5ac9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04258111","created_at":"2021-01-18T20:41:43.480Z","updated_at":"2024-07-02T16:36:03.745Z","phase":"Phase 2","brief_title":"IBI310 in Combination With Sintilimab in Patients With DNA Mismatch Repair Deficient (dMMR)/Microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04258111","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Tabosun (ipilimumab N01 injection)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 4","initiation":"Initiation: 08/27/2020","start_date":" 08/27/2020","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 05/01/2023","study_completion_date":" 05/01/2023","last_update_posted":"2022-09-19"},{"id":"785cf943-f46d-41b5-a744-2198e88473ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05165407","created_at":"2021-12-21T15:53:36.458Z","updated_at":"2024-07-02T16:36:19.281Z","phase":"Phase 2","brief_title":"Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC","source_id_and_acronym":"NCT05165407","lead_sponsor":"Peking University","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Sulanda (surufatinib) • Tabosun (ipilimumab N01 injection)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2021-12-21"}]